-
1
-
-
0037154192
-
Disease modifying therapies in multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines
-
Goodin DS, Frohman EM, Garmany GP et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 58, 169-178 (2002).
-
(2002)
Neurology
, vol.58
, pp. 169-178
-
-
Goodin, D.S.1
Frohman, E.M.2
Garmany, G.P.3
-
2
-
-
22844445587
-
Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease
-
Van Assche G, Van Ranst M, Sciot R et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N. Engl. J. Med. 353, 362-368 (2005).
-
(2005)
N. Engl. J. Med.
, vol.353
, pp. 362-368
-
-
Van Assche, G.1
Van Ranst, M.2
Sciot, R.3
-
3
-
-
22844445230
-
Progressive multifocal leukoencephalopathy in a patient treated with natalizumab
-
Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N. Engl. J. Med. 353, 375-381 (2005).
-
(2005)
N. Engl. J. Med.
, vol.353
, pp. 375-381
-
-
Langer-Gould, A.1
Atlas, S.W.2
Green, A.J.3
Bollen, A.W.4
Pelletier, D.5
-
5
-
-
22844438117
-
Progressive multifocal leukoencephalopathy and natalizumab - Unforeseen consequences
-
Berger JR, Koralnik IJ. Progressive multifocal leukoencephalopathy and natalizumab - unforeseen consequences. N. Engl. J. Med 353, 414-416 (2005).
-
(2005)
N. Engl. J. Med
, vol.353
, pp. 414-416
-
-
Berger, J.R.1
Koralnik, I.J.2
-
6
-
-
0037029424
-
Multiple sclerosis
-
Compston A, Coles A. Multiple sclerosis. Lancet 359, 1221-1231 (2002). Excellent review of the immunopathology of multiple sclerosis.
-
(2002)
Lancet
, vol.359
, pp. 1221-1231
-
-
Compston, A.1
Coles, A.2
-
7
-
-
0036788406
-
Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time
-
Kuhlmann T, Lingfeld G, Bitsch A, Schuchardt J, Bruck W. Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. Brain 125, 2202-2212 (2002).
-
(2002)
Brain
, vol.125
, pp. 2202-2212
-
-
Kuhlmann, T.1
Lingfeld, G.2
Bitsch, A.3
Schuchardt, J.4
Bruck, W.5
-
8
-
-
16844364980
-
Cortical lesions in multiple sclerosis: Combined postmortem MR imaging and histopathology
-
Geurts JJ, Bo L, Pouwels PJ et al. Cortical lesions in multiple sclerosis: combined postmortem MR imaging and histopathology. Am. J. Neuroradiol. 26, 572-577 (2005).
-
(2005)
Am. J. Neuroradiol.
, vol.26
, pp. 572-577
-
-
Geurts, J.J.1
Bo, L.2
Pouwels, P.J.3
-
9
-
-
7444260812
-
Relating neocortical pathology to disability progression in multiple sclerosis using MRI
-
Chen JT, Narayanan S, Collins DL, Smith SM, Matthews PM, Arnold DL. Relating neocortical pathology to disability progression in multiple sclerosis using MRI. Neuroimage 23, 1168-1175 (2004).
-
(2004)
Neuroimage
, vol.23
, pp. 1168-1175
-
-
Chen, J.T.1
Narayanan, S.2
Collins, D.L.3
Smith, S.M.4
Matthews, P.M.5
Arnold, D.L.6
-
10
-
-
2442532533
-
How the brain repairs itself: New therapeutic strategies in inflammatory and degenerative CNS disorders
-
Martino G. How the brain repairs itself: new therapeutic strategies in inflammatory and degenerative CNS disorders. Lancet Neurol. 3(6), 372-378 (2004). Controversial and important contribution to the field of neuroprotection and immunomodulation in repair and regeneration.
-
(2004)
Lancet Neurol.
, vol.3
, Issue.6
, pp. 372-378
-
-
Martino, G.1
-
11
-
-
23944444890
-
IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel
-
Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J. Exp. Med. 202, 1-5 (2005).
-
(2005)
J. Exp. Med.
, vol.202
, pp. 1-5
-
-
Lennon, V.A.1
Kryzer, T.J.2
Pittock, S.J.3
Verkman, A.S.4
Hinson, S.R.5
-
12
-
-
1342345214
-
The CD4-Th1 model for multiple sclerosis: A crucial re-appraisal
-
Lassmann H, Ransohoff RM. The CD4-Th1 model for multiple sclerosis: a crucial re-appraisal. Trends Immunol. 25, 132-137 (2004).
-
(2004)
Trends Immunol.
, vol.25
, pp. 132-137
-
-
Lassmann, H.1
Ransohoff, R.M.2
-
13
-
-
0342906187
-
Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination
-
Lucchinetti C, Bruck W, Parisi J et al. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann. Neurol. 47(6), 707-177 (2000).
-
(2000)
Ann. Neurol.
, vol.47
, Issue.6
, pp. 707-1177
-
-
Lucchinetti, C.1
Bruck, W.2
Parisi, J.3
-
14
-
-
17644398787
-
Anti{a}4 integrin therapy for multiple sclerosis: Mechanisms and rationale
-
Rice GPA, Hartung HP, Calabresi PA. Anti{a}4 integrin therapy for multiple sclerosis: mechanisms and rationale. Neurology 64, 1336-1342 (2005). Review of the mechanistic studies of very late antigen (VLA)-4 blockade in disease.
-
(2005)
Neurology
, vol.64
, pp. 1336-1342
-
-
Rice, G.P.A.1
Hartung, H.P.2
Calabresi, P.A.3
-
15
-
-
20844454381
-
Blocking adhesion molecules as therapy for multiple sclerosis: Natalizumab
-
Steinman L. Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab. Nature Rev. Drug Discov. 4, 510-518 (2005).
-
(2005)
Nature Rev. Drug Discov.
, vol.4
, pp. 510-518
-
-
Steinman, L.1
-
16
-
-
3042739652
-
Natalizumab: α4-integrin antagonist selective adhesion molecule inhibitors for MS
-
Rudick RA, Sandrock A. Natalizumab: α4-integrin antagonist selective adhesion molecule inhibitors for MS. Expert Rev. Neurother. 4, 571-580 (2004).
-
(2004)
Expert Rev. Neurother.
, vol.4
, pp. 571-580
-
-
Rudick, R.A.1
Sandrock, A.2
-
17
-
-
0344496250
-
Novel approaches to treating inflammatory bowel disease: Targeting α4 integrin
-
Sandborn WJ, Yednock TA. Novel approaches to treating inflammatory bowel disease: targeting α4 integrin. Am. J. Gastroenterol. 98(11), 2372-2382 (2003).
-
(2003)
Am. J. Gastroenterol.
, vol.98
, Issue.11
, pp. 2372-2382
-
-
Sandborn, W.J.1
Yednock, T.A.2
-
18
-
-
0034123924
-
Differential adhesion molecule requirements for immune surveillance and inflammatory recruitment
-
Carrithers MD, Visintin I, Kang SJ, Janeway CA Jr. Differential adhesion molecule requirements for immune surveillance and inflammatory recruitment. Brain 123, 1092-1101 (2000).
-
(2000)
Brain
, vol.123
, pp. 1092-1101
-
-
Carrithers, M.D.1
Visintin, I.2
Kang, S.J.3
Janeway Jr., C.A.4
-
19
-
-
0037413467
-
A controlled trial of natalizumab for relapsing multiple sclerosis
-
Miller DH, Khan OA, Sheremata WA et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 348, 15-23 (2003).
-
(2003)
N. Engl. J. Med.
, vol.348
, pp. 15-23
-
-
Miller, D.H.1
Khan, O.A.2
Sheremata, W.A.3
-
25
-
-
0035003051
-
Placebo-controlled clinical trials in multiple sclerosis: Ethical considerations. National Multiple Sclerosis Society (USA) Task Force on Placebo-Controlled Clinical Trials in MS
-
Lublin FD, Reingold SC. Placebo-controlled clinical trials in multiple sclerosis: ethical considerations. National Multiple Sclerosis Society (USA) Task Force on Placebo-Controlled Clinical Trials in MS. Ann. Neurol. 49, 677-681 (2001).
-
(2001)
Ann. Neurol.
, vol.49
, pp. 677-681
-
-
Lublin, F.D.1
Reingold, S.C.2
-
26
-
-
0142122890
-
Scientific and ethical issues in the use of placebo and active controls in clinical trials
-
Ellenberg SS. Scientific and ethical issues in the use of placebo and active controls in clinical trials. J. Bone Miner. Res. 18, 1121 (2003).
-
(2003)
J. Bone Miner. Res.
, vol.18
, pp. 1121
-
-
Ellenberg, S.S.1
-
27
-
-
0035922438
-
The ethics of placebo-controlled trials - A middle ground
-
Emanuel EJ, Miller FG. The ethics of placebo-controlled trials - a middle ground. N. Engl. J. Med. 345, 915-918 (2001).
-
(2001)
N. Engl. J. Med.
, vol.345
, pp. 915-918
-
-
Emanuel, E.J.1
Miller, F.G.2
-
28
-
-
4143062563
-
Oversight of human participants research: Identifying problems to evaluate reform proposals
-
Emanuel EJ, Wood A, Fleischman A et al. Oversight of human participants research: identifying problems to evaluate reform proposals. Ann. Intern. Med. 141, 282-291 (2004). Reviews and provides important context for the issues surrounding clinical trial design using placebo.
-
(2004)
Ann. Intern. Med.
, vol.141
, pp. 282-291
-
-
Emanuel, E.J.1
Wood, A.2
Fleischman, A.3
-
29
-
-
22544448947
-
Obstacles and opportunities in translational research
-
Horig H, Marincola E, Marincola FM. Obstacles and opportunities in translational research. Nature Med. 11, 705 (2005).
-
(2005)
Nature Med.
, vol.11
, pp. 705
-
-
Horig, H.1
Marincola, E.2
Marincola, F.M.3
-
30
-
-
0035849993
-
Research involving human subjects in developing countries
-
Koski G, Nightingale SL. Research involving human subjects in developing countries. N. Engl. J. Med. 342 (2001).
-
(2001)
N. Engl. J. Med.
, pp. 342
-
-
Koski, G.1
Nightingale, S.L.2
-
31
-
-
0037070795
-
Placebo-controlled trials and the Declaration of Helsinki
-
Lewis JA, Kreutz G, Sampaio C, van Zwieten-Boot B. Placebo-controlled trials and the Declaration of Helsinki. Lancet 359, 1337-40 (2002).
-
(2002)
Lancet
, vol.359
, pp. 1337-1340
-
-
Lewis, J.A.1
Kreutz, G.2
Sampaio, C.3
Van Zwieten-Boot, B.4
-
32
-
-
0035003051
-
Placebo-controlled clinical trials in multiple sclerosis: Ethical considerations. National Multiple Sclerosis Society (USA) Task Force on Placebo-Controlled Clinical Trials in MS
-
Lublin FD, Reingold SC. Placebo-controlled clinical trials in multiple sclerosis: ethical considerations. National Multiple Sclerosis Society (USA) Task Force on Placebo-Controlled Clinical Trials in MS. Ann. Neurol. 49(5), 677-681 (2001).
-
(2001)
Ann. Neurol.
, vol.49
, Issue.5
, pp. 677-681
-
-
Lublin, F.D.1
Reingold, S.C.2
-
33
-
-
0036946212
-
Clinical trials at AHCs: The perspective of an academic clinical trials office
-
Paller MS, Hostetler L, Dykhuis DA. Clinical trials at AHCs: The perspective of an academic clinical trials office. Acad. Med. 77, 1201-1206 (2000).
-
(2000)
Acad. Med.
, vol.77
, pp. 1201-1206
-
-
Paller, M.S.1
Hostetler, L.2
Dykhuis, D.A.3
-
34
-
-
0034687109
-
The ethics of placebo-controlled trials
-
Reynolds T. The ethics of placebo-controlled trials. Ann. Intern. Med. 133, 491-492 (2000).
-
(2000)
Ann. Intern. Med.
, vol.133
, pp. 491-492
-
-
Reynolds, T.1
-
35
-
-
0035849989
-
Ethical issues in the design and conduct of clinical trials in developing countries
-
Shapiro HT, Meslin EM. Ethical issues in the design and conduct of clinical trials in developing countries. N. Engl. J. Med. 345 (2001).
-
(2001)
N. Engl. J. Med.
, pp. 345
-
-
Shapiro, H.T.1
Meslin, E.M.2
-
36
-
-
0142091166
-
The ethics of placebo-controlled trials
-
Weijer C. The ethics of placebo-controlled trials. J. Bone Miner. Res. 18, 1150-1153 (2003).
-
(2003)
J. Bone Miner. Res.
, vol.18
, pp. 1150-1153
-
-
Weijer, C.1
-
37
-
-
0031744008
-
The Mayo Clinic-Canadian Cooperative trial of sulfasalazine in active multiple sclerosis
-
Noseworthy JH, O'Brien P, Erickson BJ et al. The Mayo Clinic-Canadian Cooperative trial of sulfasalazine in active multiple sclerosis. Neurology 51, 1342-1352 (1998).
-
(1998)
Neurology
, vol.51
, pp. 1342-1352
-
-
Noseworthy, J.H.1
O'Brien, P.2
Erickson, B.J.3
-
39
-
-
0035052096
-
Discordant effects of anti-VLA-4 treatment before and after onset of relapsing experimental autoimmune encephalomyelitis
-
Theien BE, Vanderlugt CL, Eagar TN et al. Discordant effects of anti-VLA-4 treatment before and after onset of relapsing experimental autoimmune encephalomyelitis. J. Clin. Invest. 107, 995-1006 (2001).
-
(2001)
J. Clin. Invest.
, vol.107
, pp. 995-1006
-
-
Theien, B.E.1
Vanderlugt, C.L.2
Eagar, T.N.3
-
40
-
-
0344305462
-
Differential effects of treatment with a small-molecule VLA-4 antagonist before and after onset of relapsing EAE
-
Theien BE, Vanderlugt CL, Nickerson-Nutter C et al. Differential effects of treatment with a small-molecule VLA-4 antagonist before and after onset of relapsing EAE. Blood 102, 4464-4471 (2003).
-
(2003)
Blood
, vol.102
, pp. 4464-4471
-
-
Theien, B.E.1
Vanderlugt, C.L.2
Nickerson-Nutter, C.3
-
41
-
-
0037097524
-
JC virus load in progressive multifocal leukoencephalopathy: Analysis of the correlation between the viral burden in cerebrospinal fluid, patient survival, and the volume of neurological lesions
-
Garcia De Viedma D, Diaz Infantes M, Miralles P et al. JC virus load in progressive multifocal leukoencephalopathy: analysis of the correlation between the viral burden in cerebrospinal fluid, patient survival, and the volume of neurological lesions. Clin. Infect. Dis. 34, 1568-1575 (2002).
-
(2002)
Clin. Infect. Dis.
, vol.34
, pp. 1568-1575
-
-
Garcia De Viedma, D.1
Diaz Infantes, M.2
Miralles, P.3
-
42
-
-
11144239958
-
Establishment of an immunoscreening system using recombinant VP1 protein for the isolation of a monoclonal antibody that blocks JC virus infection
-
Henmi C, Sawa H, Iwata H Orba Y, Tanaka S, Nagashima K. Establishment of an immunoscreening system using recombinant VP1 protein for the isolation of a monoclonal antibody that blocks JC virus infection. Biochem. Biophys. Res. Commun. 327, 242-251 (2005).
-
(2005)
Biochem. Biophys. Res. Commun.
, vol.327
, pp. 242-251
-
-
Henmi, C.1
Sawa, H.2
Iwata, H.3
Orba, Y.4
Tanaka, S.5
Nagashima, K.6
-
43
-
-
0037374763
-
α4β1 integrin acts as a cell receptor for murine polyomavirus at the postattachment level
-
Caruso M, Belloni L, Sthandier O, Amati P, Garcia MI. α4β1 integrin acts as a cell receptor for murine polyomavirus at the postattachment level. J. Virol. 77, 3913-3921 (2003).
-
(2003)
J. Virol.
, vol.77
, pp. 3913-3921
-
-
Caruso, M.1
Belloni, L.2
Sthandier, O.3
Amati, P.4
Garcia, M.I.5
-
44
-
-
16644393095
-
The JC virus-like particle overlay assay
-
Sawa H, Komagome R. The JC virus-like particle overlay assay. Methods Mol. Biol. 292, 175-86 (2005).
-
(2005)
Methods Mol. Biol.
, vol.292
, pp. 175-186
-
-
Sawa, H.1
Komagome, R.2
-
45
-
-
2642572579
-
New insights into progressive multifocal leukoencephalopathy
-
Koralnik IJ. New insights into progressive multifocal leukoencephalopathy. Curr. Opin. Neurol. 17, 376-370 (2004).
-
(2004)
Curr. Opin. Neurol.
, vol.17
, pp. 376-1370
-
-
Koralnik, I.J.1
-
46
-
-
0034103105
-
The HHV6 paradox: Ubiquitous commensal or insidious pathogen? A two-step in situ PCR approach
-
Blumberg BM, Mock DJ, Powers JM et al. The HHV6 paradox: ubiquitous commensal or insidious pathogen? A two-step in situ PCR approach. J. Clin. Virol. 16, 159-178 (2000).
-
(2000)
J. Clin. Virol.
, vol.16
, pp. 159-178
-
-
Blumberg, B.M.1
Mock, D.J.2
Powers, J.M.3
-
47
-
-
0037988716
-
Human herpesvirus 6 genome and antigen in acute multiple sclerosis lesions
-
Goodman AD, Mock DJ, Powers JM, Baker JV, Blumberg BM. Human herpesvirus 6 genome and antigen in acute multiple sclerosis lesions. J. Infect. Dis. 187, 1365-1376 (2003).
-
(2003)
J. Infect. Dis.
, vol.187
, pp. 1365-1376
-
-
Goodman, A.D.1
Mock, D.J.2
Powers, J.M.3
Baker, J.V.4
Blumberg, B.M.5
-
48
-
-
4444294103
-
Increased CXCL8 (IL-8) expression in multiple sclerosis
-
Lund BT, Ashikian N, Ta HQ et al. Increased CXCL8 (IL-8) expression in multiple sclerosis. J. Neuroimmunol. 155, 161-171 (2004).
-
(2004)
J. Neuroimmunol.
, vol.155
, pp. 161-171
-
-
Lund, B.T.1
Ashikian, N.2
Ta, H.Q.3
-
49
-
-
19944427487
-
Investigation of human brain tumors for the presence of polyomavirus genome sequences by two independent laboratories
-
Rollison DE, Utaipat U, Ryschkewitsch C et al. Investigation of human brain tumors for the presence of polyomavirus genome sequences by two independent laboratories. Int. J. Cancer 113, 769-774 (2005).
-
(2005)
Int. J. Cancer
, vol.113
, pp. 769-774
-
-
Rollison, D.E.1
Utaipat, U.2
Ryschkewitsch, C.3
|